Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V GLASS

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|July 12, 2005
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosisHarry K Genant, Johan Halse, Walter G Briney, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 20, 2008
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronateR A Wermers, C P Recknor, F Cosman, et al.
Plant, Cell & Environment|March 11, 2015
Force-displacement measurements of earlywood bordered pits using a mesomechanical testerSamuel L Zelinka, Keith J Bourne, John C Hermanson, et al.
The Journal of Bone and Joint Surgery. American Volume|June 3, 2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trialsMary L Bouxsein, Peiqi Chen, Emmett V Glass, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2009
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agentFelicia Cosman, Robert A Wermers, Christopher Recknor, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2006
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosisTony M Keaveny, David W Donley, Paul F Hoffmann, et al.
Borderline Personality Disorder and Emotion Dysregulation|March 9, 2023
Dissociative experiences of adolescents with borderline personality disorder: description and predictionMary C Zanarini, Eduardo Martinho, Christina M Temes, et al.
Journal of Personality Disorders|December 1, 2023
The 8-Year Course of Acute Physical Pain Reported by Patients With Borderline Personality Disorder and Comparison Subjects With Other Personality DisordersAlma M Bitran, Christina M Temes, Tess C Gecha, et al.
The American Journal on Addictions|February 26, 2025
The 24-year course of substance use disorders in patients with borderline personality disorder and personality-disordered comparison subjectsMary C Zanarini, Christina M Temes, Isabel V Glass, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 10, 2006
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysisM C Nevitt, P Chen, D P Kiel, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|July 12, 2005
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosisHarry K Genant, Johan Halse, Walter G Briney, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 20, 2008
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronateR A Wermers, C P Recknor, F Cosman, et al.
Plant, Cell & Environment|March 11, 2015
Force-displacement measurements of earlywood bordered pits using a mesomechanical testerSamuel L Zelinka, Keith J Bourne, John C Hermanson, et al.
The Journal of Bone and Joint Surgery. American Volume|June 3, 2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trialsMary L Bouxsein, Peiqi Chen, Emmett V Glass, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2009
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agentFelicia Cosman, Robert A Wermers, Christopher Recknor, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2006
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosisTony M Keaveny, David W Donley, Paul F Hoffmann, et al.
Borderline Personality Disorder and Emotion Dysregulation|March 9, 2023
Dissociative experiences of adolescents with borderline personality disorder: description and predictionMary C Zanarini, Eduardo Martinho, Christina M Temes, et al.
Journal of Personality Disorders|December 1, 2023
The 8-Year Course of Acute Physical Pain Reported by Patients With Borderline Personality Disorder and Comparison Subjects With Other Personality DisordersAlma M Bitran, Christina M Temes, Tess C Gecha, et al.
The American Journal on Addictions|February 26, 2025
The 24-year course of substance use disorders in patients with borderline personality disorder and personality-disordered comparison subjectsMary C Zanarini, Christina M Temes, Isabel V Glass, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 10, 2006
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysisM C Nevitt, P Chen, D P Kiel, et al.
Pageof 5